Skip to main content

Table 6 Statistical analysis of the difference between proportions of NVP-related adverse reactions of skin and liver

From: Assessment of the nevirapine safety signal using data from the national antiretroviral dispensing database: a retrospective study

   

% (95 % CI)

 

Adverse reaction type

2011

Previous years

P-value

ARV

Related reactions (all)

80.9 % (77.4 %–84.4 %)

81.3 % (78.1 %–84.5 %)

0.87

NVP-related

Skin and liver

43.2 % (38.7 %–47.7 %)

16.7 % (13.7 %–19.7 %)

<0.0001

Skin (all)

31.2 % (27.0 %–35.5 %)

11.8 % (9.2 %–14.4 %)

<0.0001

Skin: severe

22.7 % (18.9 %–26.5 %)

5.6 % (3.7 %%–7.5 %)

<0.0001

Skin: mild/moderate

8.5 % (6.0 %–11.0 %)

6.2 % (4.2 %–8.2 %)

0.16

Liver (all)

12.1 % (9.2 %–15.0 %)

4.9 % (3.1 %–6.7 %)

<0.0001

Liver: severe

8.5 % (6.0 %–11.0 %)

2.2 % (1.0 %–3.4 %)

<0.0001

Liver: mild/moderate

2.7 % (1.0 %–4.4 %)

2.4 % (1.2 %–3.6 %)

0.73

Other medicines

Skin and liver

5.0 % (3.0 %–7.0 %)

9.9 % (7.5 %–12.3 %)

0.002

NVP-related reactions for

Females

29.5 % (25.4 %–33.6 %)

12.5 % (9.8 %–15.2 %)

<0.0001

Females: severe

21.6 % (17.9 %–25.3 %)

5.6 % (3.7 %–7.5 %)

<0.0001

Females: skin-severe

17.3 % (13.9 %–20.7 %)

4.0 % (2.4 %–5.6 %)

<0.0001

Females: liver-severe

4.3 % (2.5 %–6.1 %)

1.5 % (0.5 %–2.5 %)

0.0072

Males

13.7 % (10.6 %–16.8 %)

3.9 % (2.3 %–5.5 %)

<0.0001

Males: severe

9.6 % (6.9 %–12.3 %)

2.2 % (1.0 %–3.4 %)

<0.0001

Males: skin-severe

5.4 % (3.4 %–7.4 %)

1.5 % (0.5 %–2.5 %)

0.0007

Males: liver-severe

4.2 % (2.4 %–6.0 %)

0.7 % (0.0 %–1.4 %)

0.0003

  1. The results in the above table show that there was an increase in proportion of reports of severe reactions to NVP, on the skin and liver. The results also show that there was no increase in the mild and moderate reactions